Blueprint Medicines Corp (BPMC)
94.15
-2.47
(-2.56%)
USD |
NASDAQ |
Nov 22, 16:00
94.20
+0.05
(+0.05%)
After-Hours: 20:00
Blueprint Medicines Profit Margin (Quarterly): -43.90% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -43.90% |
| June 30, 2024 | -36.19% |
| March 31, 2024 | 92.74% |
| December 31, 2023 | -154.1% |
| September 30, 2023 | -236.4% |
| June 30, 2023 | -230.7% |
| March 31, 2023 | -204.7% |
| December 31, 2022 | -409.1% |
| September 30, 2022 | -201.8% |
| June 30, 2022 | -437.0% |
| March 31, 2022 | -169.0% |
| December 31, 2021 | -297.8% |
| September 30, 2021 | -484.7% |
| June 30, 2021 | -397.3% |
| March 31, 2021 | -462.2% |
| December 31, 2020 | -251.2% |
| September 30, 2020 | 85.08% |
| June 30, 2020 | -1.48K% |
| March 31, 2020 | -1.80K% |
| December 31, 2019 | -128.7% |
| Date | Value |
|---|---|
| September 30, 2019 | -1.03K% |
| June 30, 2019 | -1.95K% |
| March 31, 2019 | -11.97K% |
| December 31, 2018 | -7.78K% |
| September 30, 2018 | -6.64K% |
| June 30, 2018 | -65.27% |
| March 31, 2018 | -5.93K% |
| December 31, 2017 | -3.01K% |
| September 30, 2017 | -467.3% |
| June 30, 2017 | -567.3% |
| March 31, 2017 | -479.1% |
| December 31, 2016 | -276.5% |
| September 30, 2016 | -273.3% |
| June 30, 2016 | -267.4% |
| March 31, 2016 | -226.1% |
| December 31, 2015 | -336.0% |
| September 30, 2015 | -369.0% |
| June 30, 2015 | -483.1% |
| March 31, 2015 | -1.77K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.80K%
Minimum
Mar 2020
92.74%
Maximum
Mar 2024
-362.3%
Average
-233.5%
Median
Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 14.22% |
| Regeneron Pharmaceuticals Inc | 36.03% |
| NovaBay Pharmaceuticals Inc | -49.65% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -50.13% |
| Return on Assets | -11.44% |
| Return on Invested Capital | -23.14% |
| Gross Profit Margin (Quarterly) | 98.49% |
| Operating Margin (Quarterly) | -38.21% |
| Return on Net Operating Assets | -67.45% |